Search

Gedatolisib

breast cancer without a PIK3CA mutation detected, following progression on or after at least one line of endocrine therapy in the metastatic setting. … [L63796,L63927] The PI3K/AKT/mTOR pathway is a long-standing target in the breast cancer setting, with previously approved agents acting on a single node of it (i.e. PI3Kα, AKT, or mTORC1).

Phenoxybenzamine

It has been used to treat hypertension and as a peripheral vasodilator.

Berberine

It is also found in many other plants. It is relatively toxic parenterally, but has been used orally for various parasitic and fungal infections and as antidiarrheal.

Etofamide

Etofamide is used as an antiamoebic agent. Etofamide, under the brand name Kitnos, was marketed in Brazil by Pfizer but has been discontinued [L5617].

Radium Ra 223 dichloride

It was first approved by the FDA in May 2013 and is currently marketed under the brand name Xofigo, which was formerly called Alpharadin. … As a cation, radium mimics calicum and binds to hydroxyapatite, which is a bone mineral found in areas of high bone turnover as seen in bone metastases.

Clascoterone

It binds to androgen receptors with high affinity. … [L15621] Clascoterone is also being investigated as a novel treatment for androgenetic alopecia.[A218766]

Garadacimab

[L53283] It was developed by CSL Behring for use as a prophylactic agent in patients with hereditary angioedema (HAE), a rare autosomal dominant disorder that results in acute episodes of angioedema. … [L53283,A273998] Garadacimab received its first approval in Australia and the UK in January 2025, and has since been approved in a number of other jurisdictions, including the EU and Japan.

Difamilast

It is approved in Japan and the United States.[L55042, A275424, L56052] … [L56052, A275420] This skin disease occurs most frequently in children and can have an onset as early as within the first 2 years of life.

Chromous sulfate

Zolbetuximab

[A264723] Zolbetuximab was approved by the FDA in October 2024 for use in patients with HER2 negative, CLDN18.2-positive gastric and GEJ adenocarcinomas.[L51943,L51923] … [L51923] It is specifically targeted against CLDN18.2, a membrane protein normally found in gastric mucosal cells which is overexpressed in 30-50% of gastric and gastroesophageal junction (GEJ) adenocarcinomas